First single-dose RSV vaccine approved in Europe
Pharmaceutical companies Sanofi and AstraZeneca announced Friday that the European Commission had approved nirsevimab, a lab-developed antibody created to shield infants from their first encounter with RSV, or respiratory syncytial virus, a highly contagious common infection that affects nearly all children by the age of two.
RSV, also known as the respiratory syncytial virus, is depicted in an electron microscope in this 1981 image from the Centers for Disease Control and Prevention (CDC). via AP/File, CDC
The first single-dose medication in the world against a respiratory virus that sickens millions of infants and children year has been approved by the European Commission.
Pharmaceutical companies Sanofi and AstraZeneca announced Friday that the European Commission had approved nirsevimab, a lab-developed antibody created to shield infants from their first encounter with RSV, or respiratory syncytial virus, a highly contagious common infection that affects nearly all children by the age of two.
Currently, babies at high risk of contracting the illness can receive monthly vaccinations to safeguard them throughout RSV season.
Based on cutting-edge research that showed the medication reduced the likelihood that babies with RSV needed medical attention and appeared to be safe, compared to infants who received a dummy treatment, the European Medicines Agency recommended that nirsevimab, marketed as Beyfortus, be authorised in September. The medication is injected all at once.
Silke Mader, co-founder of the European Foundation for the Care of Newborn Infants, expressed excitement at the chance to extend prevention efforts to all infants.
DailyObjects has a new smart phone cover with Indian aesthetics and roots...Premium
A new smart phone cover from DailyObjects features Indian aesthetics and heritage.
Cash on hand has reached a record level of Rs. 30.88 trillion.
Premium
Cash on hand has reached a record level of Rs. 30.88 trillion.
Inside Track - Coomi Kapoor reports a postponement of the New Parliament deadline.
Premium
Inside Track - Coomi Kapoor reports a postponement of the New Parliament deadline.
Morbi, according to Tavleen Singh, was more than a catastrophe.
Premium
Morbi, according to Tavleen Singh, was more than a catastrophe.
Join today for less than Rs 4 per day.
RSV is this year's early cause of an infection rise in children's hospitals in the U.S. Health officials in Europe are issuing a warning that there may be a similar increase throughout the continent.
RSV typically causes a cold-like annoyance for healthy persons. For the old and the very young, the infection, however, can be fatal. The virus can cause severe lung infection, and in young babies, it can make it difficult for them to breathe by inflaming their small airways. Every year, RSV claims the lives of roughly 100,000 newborns, usually in developing nations. Nirsevimab is an antibody that was created to provide newborns and infants with instant protection against RSV and stop infections in their respiratory systems.
NEWS IN DELHI
Asthma cases among youngsters in Delhi are on the rise, and experts attribute this to pollution. 2 On Sunday morning, the AQI in Delhi drops to 345.
How is construction on the new Parliament building going?
Continued from Delhi
After decades of unsuccessful attempts to create an effective injection, Pfizer earlier this week revealed early studies suggesting that a new vaccine given to pregnant women could help protect their kids against RSV.
Comments
Post a Comment